These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 22500149

  • 1. Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.
    Nadin C.
    Core Evid; 2005; 1(2):125-41. PubMed ID: 22500149
    [Abstract] [Full Text] [Related]

  • 2. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 3. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2005 May; 23(10):1057-72. PubMed ID: 16235978
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 5. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 6. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL, Nappi JM.
    Clin Ther; 2003 Nov 14; 25(11):2647-68. PubMed ID: 14693297
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 14; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Apr 14; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 10. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Apr 03; 5(5):354-63. PubMed ID: 14503934
    [Abstract] [Full Text] [Related]

  • 11. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 03; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 12. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
    Verma A, Solomon SD.
    Curr Heart Fail Rep; 2007 Dec 03; 4(4):183-9. PubMed ID: 18221614
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Review article: eplerenone: an underused medication?
    Abuannadi M, O'Keefe JH.
    J Cardiovasc Pharmacol Ther; 2010 Dec 03; 15(4):318-25. PubMed ID: 20876342
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F.
    Circulation; 2012 Jan 17; 125(2):271-9. PubMed ID: 22128223
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, Tromp J, Rossignol P, Zannad F.
    Circ Heart Fail; 2018 Jul 17; 11(7):e004926. PubMed ID: 29997240
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.